Active Research Project
Investigator(s):
Ching H. Tung, Ph.D.
Related Institute:
Last Updated:
June 9, 2022
The Tung lab has pioneered a layer-by-layer fabrication technology for nucleic acid-containing therapeutics, including small interfering RNAs (siRNAs), micro RNAs (miRNAs), peptides, and their combinations. The prepared nanovectors effectively deliver multiple active components, thereby boosting therapeutic efficacy with minimal off‐target effects. The lab has demonstrated the nanovectors' potential clinical applications in breast cancer and pancreatic cancer models.
Publications: Versatile nanodelivery platform to maximize siRNA combination therapy, Macromol. Biosci.: 2017, 17, 1600294. PMID: 27654639; Nanoparticle delivery of miR-708 mimetic impairs breast cancer metastasis. Mol. Cancer Ther.: 2019, 18, 579-591. PMID: 30679387.